KEVIN C OBOYLE
CIK 1203567 · CFO and Executive VP · last filed 2026-06-22
KEVIN C OBOYLE is a CFO and Executive VP who has filed 129 SEC Form 4 insider transactions across 13 companies since 2007. The most recent filing, for CARL, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$14.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $969.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$969.6K
13
129
-$14.26M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CARL | Director | 31,031 | $12.31 | $382.0K | $0 | 2 | 2026-06-22 |
| OM | Director | 34,785 | $4.72 | $164.2K | $0 | 3 | 2026-06-05 |
| IRTC | Director | 3,608 | $117.37 | $423.5K | $0 | 2 | 2026-05-29 |
| NEVRO CORP (NVRO) Delisted | Director | 0 | $5.84 | $0 | $301.6K | 10 | 2025-04-03 |
| Sientra, Inc. (SIEN) Delisted | Director | 22,098 | $0.17 | $3.8K | $150.0K | 10 | 2022-06-13 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | Director | 0 | $24.04 | $0 | $3.5K | 19 | 2021-04-22 |
| Wright Medical Group N.V. (WMGI) Delisted | Director | 16,306 | — | — | $0 | 1 | 2019-07-30 |
| Wright Medical Group N.V. (WMGIZ) Delisted | Director | 12,390 | — | — | -$1.82M | 7 | 2019-03-05 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | Director | 0 | — | — | -$2.40M | 17 | 2017-04-28 |
| Wright Medical Group N.V. (WMGI.Z) Delisted | Director | 17,053 | — | — | $0 | 4 | 2016-10-17 |
| Wright Medical Group N.V. (TRNX) Delisted | Director | 1 | — | — | $0 | 14 | 2015-08-14 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 0 | — | — | $0 | 2 | 2014-11-18 |
| NUVASIVE INC (NUVA) Delisted | CFO and Executive VP | 46,315 | $39.75 | $1.84M | -$10.49M | 37 | 2009-12-17 |
Recent Filings
129 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | CARL | Grant (A) | +13,698 | $0 | EDGAR |
| 2026-06-05 | OM | Grant (A) | +10,667 | $0 | EDGAR |
| 2026-05-29 | IRTC | Grant (A) | +1,573 | $0 | EDGAR |
| 2025-07-24 | CARL | Grant (A) | +17,333 | $0 | EDGAR |
| 2025-07-08 | IRTC | Grant (A) | +2,035 | $0 | EDGAR |
| 2025-06-04 | OM | Grant (A) | +8,983 | $0 | EDGAR |
| 2025-05-14 | OM | Grant (A) | +15,135 | $0 | EDGAR |
| 2025-04-03 | NEVRO CORP (NVRO) Delisted | Disp (D) | −43,396 | $0 | EDGAR |
| 2024-05-28 | NEVRO CORP (NVRO) Delisted | Grant (A) | +19,169 | $0 | EDGAR |
| 2023-05-30 | NEVRO CORP (NVRO) Delisted | Grant (A) | +6,754 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.